Description

Primary Mendelian randomization results showing the estimated causal effect of omega-3 PUFA supplementation on inflammatory bowel disease risk, addressing conflicting epidemiological evidence.

Figure 3

Chart

Source Paper

Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: A Mediation Mendelian Randomization Study.

Metabolites (2023)

PMID: 37887366

DOI: 10.3390/metabo13101041

Cite This Figure

![Figure 3: Primary Mendelian randomization results showing the estimated causal effect of omega-3 PUFA supplementation on inflammatory bowel disease risk, addressing conflicting epidemiological evidence.]()

> Source: Xiaojing Jia et al. "Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bo." *Metabolites*, 2023. PMID: [37887366](https://pubmed.ncbi.nlm.nih.gov/37887366/)

<figure>
  <img src="" alt="Primary Mendelian randomization results showing the estimated causal effect of omega-3 PUFA supplementation on inflammatory bowel disease risk, addressing conflicting epidemiological evidence." />
  <figcaption>Figure 3. Primary Mendelian randomization results showing the estimated causal effect of omega-3 PUFA supplementation on inflammatory bowel disease risk, addressing conflicting epidemiological evidence.<br>  Source: Xiaojing Jia et al. "Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bo." <em>Metabolites</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37887366/">37887366</a></figcaption>
</figure>

Preuves associées

Omega-3 Fatty Acids (EPA/DHA) pour Ulcerative Colitis (UC)

Note C · 8 études

Omega-3 Fatty Acids (EPA/DHA) pour Crohn's Disease

Note C · 6 études